throbber
Case 2:09~cv-00097-JRG Document 241 Filed 08!08I11 Page 1 of 165 PageID #: 6187
`
`
`
`
`
`l
`
`2
`
`IN THE UNITED STATES DISTRICT COURT
`
`
`
`
`
`
`FOR THE EASTERN DISTRICT OF TEXAS
`
`
`
`
`
`
`MARSHALL DIVISION
`
`
`
`
`
`Civil Docket No.
`2:09—CV—97
`
`
`Marshall, Texas
`
`
`
`
`
`
`
`August 3, 2011
`
`
`1:15 P.M.
`
`
`
`
`
`
`
`
`
`
`
`3 ALLERGAN,
`
`
`
`INC.
`
`
`
`
`
`.
`
`SANDOZ,
`
`
`
`INC.
`
`
`
`TRANSCRIPT OF BENCH TRIAL
`
`
`
`
`BEFORE THE HONORABLE JUDGE T.
`JOHN WARD
`
`
`
`
`
`
`
`UNITED STATES DISTRICT JUDGE
`
`
`
`
`
`
`
`4
`
`5
`
`7
`
`MS.
`JUANITA BROOKS
`
`
`
`MR. ROGER DENNING
`
`
`
`Fish & Richardson
`
`
`
`12390 El Camino Real
`
`
`
`
`
`
`San Diego, CA
`
`
`92130
`
`
`
`
`
`MR.
`JONATHAN SINGER
`
`
`MS. DEANNA REICHEL
`
`
`
`Fish & Richardson
`
`
`
`60 South Sixth Street
`
`
`
`3200 RBC Plaza
`
`
`
`
`
`Minneapolis, MN
`
`
`
`55402
`
`
`
`MR. W. CHAD SHEAR
`
`
`
`Fish & Richardson
`
`
`1717 Main Street
`
`
`
`Suite 5000
`
`
`
`
`Dallas,
`
`TX
`
`75201
`
`
`
`
`
`
`
`
`
`
`
`
`
`10 FOR THE PLAINTIFF:
`
`
`
`
`
`11
`
`12
`
`:3
`
`14
`
`15
`
`1?
`
`18
`
`20 APPEARANCES CONTINUED ON NEXT PAGE:
`
`
`
`
`
`
`
`
`21
`
`
`
`
`22 COURT REPORTERS:
`
`
`
`23
`
`24
`
`
`
`
`
`MS. SUSAN SIMMONS, CSR
`
`
`
`
`MS. SHELLY HOLMES, CSR
`
`
`
`Official Court Reporters
`
`
`
`
`l00 East Houston, Suite 125
`
`
`
`Marshall,
`75670
`TX
`903/935~3868
`
`
`
`
`
`
`25 {Proceedings recorded by mechanical stenography,
`
`
`
`
`
`transcript produced on CAT system.)
`
`
`
`
`
`
`
`Page 1 of 166
`
`SENJU EXHIBIT 2136
`
`LUPIN V. SENJU
`IPR2015-01100
`
`Page 1 of 166
`
`SENJU EXHIBIT 2136
`LUPIN v. SENJU
`IPR2015-01100
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-O0097—JRG Document 241 Filed O8/08!11 Page 2 of 165 PagelD #: 6188
`
`
`
`
`
`
`
`MS. SUSAN COLETTI
`
`
`
`MS. A. MARTINA HUFNAL
`
`
`
`
`MR. SANTOSH CONTINHO
`
`
`
`Fish & Richardson
`
`
`
`222 Delaware Avenue
`
`
`1?th Floor
`
`
`
`
`Wilmington, DE
`
`
`
`19899
`
`
`
`MR. GREGORY LOVE
`
`
`
`Stevens Love Firm
`
`
`
`
`
`
`111 West Tyler Street
`
`
`
`Longview,
`TX
`T5601
`
`
`
`
`
`
`MR. WILLIAM E.
`
`
`
`The Davis Firm
`
`
`
`111 West Tyler Street
`
`
`
`Longview,
`TX
`75601
`
`
`
`"E0" DAVIS, III
`
`
`
`
`
`MR. BARRY P. GOLOB
`
`
`
`
`MR. KERRY B. MCTIGUE
`
`
`
`
`MR. W. BLAKE COBLENTZ
`
`
`
`Duane Morris
`
`
`
`
`
`
`505 9th Street, NW
`Suite 1000
`
`
`
`
`Washington, DC
`
`20004
`
`
`
`MR. RICHARD T. RUZICH
`
`
`
`Duane Morris
`
`
`190 South Lasalle Street
`
`
`
`Suite 3700
`
`
`
`Chicago,
`IL
`
`
`
`60603
`
`
`
`
`
`
`
`
`
`
`MR. HARRY L. GILLAM,
`Gillam & Smith
`
`
`
`
`
`
`303 South Washington Avenue
`
`
`
`Marshall,
`TX
`75670
`
`JR.
`
`
`
`
`
`
`
`
`
`MR. STEPHEN P. BENSON
`
`
`
`MR. DENNIS C. LEE
`
`
`
`
`Katten Muchin Rosenman
`
`
`525 West Monroe Street
`
`
`
`Suite 1600
`
`
`
`Chicago,
`IL
`
`
`
`60661
`
`
`
`
`
`
`APPEARANCES CONTINUED:
`
`
`
`
`FOR THE PLAZNTIFF:
`
`
`
`
`
`
`
`FOR THE DEFENDANTS:
`
`
`
`(Sandoz, et al)
`
`
`
`(Apotex)
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 2 of 166
`
`Page 2 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09—CV-00O97—.]F<’G Document 241 Filed 08108111 Page 3 _Of 165 PageID #2 6189
`
`
`
`
`
`1 APPEARANCES CONTINUED:
`
`
`
`
`
`2 FOR THE DEFENDANTS:
`
`
`
`
`(Watson)
`
`
`
`MR. LARRY PHILLIPS
`
`
`
`
`
`
`Siebman Reynolds Burg &
`
`Phillips
`300 North Travis Street
`
`
`
`
`
`
`Sherman,
`TX
`75090
`
`
`
`
`
`MR. GARY E. HOOD
`
`
`
`
`
`
`Polsinelli Shughart
`161 North Clark Street
`
`
`
`Suite 4200
`
`
`
`Chicago,
`IL
`
`60601
`
`
`
`
`
`
`
`MS. ROBYN H. AST
`
`
`
`
`
`
`Polsinelli Shughart
`100 South 4th Street
`
`
`
`Suite 1000
`
`
`
`
`
`St. Louis, MO
`
`
`
`63102
`
`
`
`1|r~)r*k9r‘k**k9:‘k9r**k*:l"J:‘k9:‘k‘k9:‘k‘k*"k*9:9<:1:
`
`
`
`P R O C E E D I N G S
`
`
`
`
`
`
`
`
`
`
`
`
`
`COURT SECURITY OFFICER: All rise.
`
`
`
`
`
`
`
`THE COURT:
`
`
`
`
`Please be seated.
`
`
`
`
`
`Ms. Brooks.
`
`
`
`
`
`MS. BROOKS:
`
`
`
`
`
`
`Thank you, Your Honor.
`
`
`
`
`
`
`
`
`
`ANGELO P. TANNA, M.D., DEFENDANTS' WITNESS,
`
`
`PREVIOUSLY SWORN
`
`
`
`
`
`DIRECT EXAMINATION
`
`
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`
`
`21 BY MS. BROOKS:
`
`
`
`
`22
`
`23
`
`24
`
`
`
`
`
`
`
`.
`
`
`
`
`
`.
`
`
`
`.
`
`
`
`
`Good afternoon, Dr. Tanna.
`
`
`
`
`
`
`Good after, Ms. Brooks.
`
`
`
`
`
`
`
`Right before the lunch break,
`
`
`
`
`I was
`
`
`
`
`
`
`
`
`
`
`
`
`25 frantically looking for a Copy of Walters.
`
`
`
`
`
`We now have
`
`
`
`Page 3 of 166
`
`Page 3 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv—00O97~JRG Document 241 Filed 08l08!11 Page 4 of 165 PagelD #: 6190
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`one before you in your binder.
`
`
`
`
`
`And it's DTX138.
`
`
`
`Oh,
`
`
`
`
`
`
`
`
`
`
`I'm sorry. That's the abstract actually, which you
`
`
`
`
`
`did look at.
`
`
`
`Now,
`
`
`
`
`
`
`let's look at DTXl37.
`
`
`
`
`
`And that is
`
`
`
`
`
`the Walters paper.
`
`
`
`
`
`
`
`
`
`
`
`
`
`So you say, Dr. Tanna, you had not had a
`
`
`
`
`
`
`
`
`
`chance to look at this before rendering your opinion;
`
`
`
`is
`
`
`
`
`that right?
`
`
`
`A.
`
`
`
`No,
`
`
`
`
`
`that's not true.
`
`
`
`
`Now that
`
`
`
`
`I see it,
`
`
`I do
`
`
`
`
`recognize it.
`
`
`
`
`
`
`
`
`I have looked at this reference.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`So you did consider it in rendering your
`
`
`
`opinion?
`
`
`
`A.
`
`
`
`
`
`I did consider it, yes.
`
`
`
`
`All right.
`
`
`
`
`
`Then let's look,
`
`
`
`
`
`if we could,
`
`
`
`
`
`Q.
`
`
`
`
`
`
`please, at Bates No. 346,
`
`
`
`
`
`
`the page ending in that Bates
`
`
`
`number.
`
`
`
`
`MS. BROOKS:
`
`
`
`
`And highlight,
`
`
`
`
`
`
`if we could,
`
`
`
`
`
`
`
`
`in the right—hand column where it begins similar
`
`
`
`means —— mean decreases in IOP.
`
`
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`346?
`
`
`
`
`
`
`
`(By Ms. Brooks) Yeah, 346.
`
`
`
`
`
`
`It should be the
`
`
`
`
`
`
`bottom right~hand corner,
`
`
`
`
`the Bates No. 000346.
`
`
`
`
`
`
`
`
`
`
`Do you have that?
`
`
`
`
`Yes,
`
`
`I do.
`
`
`
`Okay.
`
`
`
`
`
`
`
`
`
`And it's also up on the screen.
`
`
`
`
`
`
`
`
`So let's see what Walters also disclosed about
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 4 of 166
`
`Page 4 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09—cv-00097—JRG Document 241 Filed 08!U8!11 Page 5 of 165 PageID #: 6191
`
`
`
`
`
`
`this study.
`
`
`
`
`It says:
`
`
`
`
`
`
`
`Similar mean decreases in IOP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`were noted for both dosing regimens at hours 2, 4, and ?
`
`
`
`in the diurnal measurements.
`
`
`
`
`
`
`
`
`
`In the three—times-daily group,
`
`
`
`
`an additional
`
`
`
`
`
`
`
`
`
`
`
`
`mean decrease in IOP of 3.5 millimeters of mercury was
`
`
`
`
`
`
`
`
`
`
`
`
`observed at hour 9, after the morning dosing, or two
`
`
`
`
`
`
`
`hours following the afternoon dosing.
`
`
`
`
`
`
`
`
`Do you see that, Dr. Tanna?
`
`
`
`Yes,
`
`
`
`
`I do.
`
`
`
`
`
`
`
`
`
`
`
`
`
`So isn't it true that one of skill in the art
`
`
`
`
`
`A.
`
`Q.
`
`would look at Walters and see that there was a
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`statistically significant decrease in IOP at 9.0 hours
`
`
`
`
`
`
`
`
`after morning dosing on the three—times—a—day
`
`
`
`Brimonidine?
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`A.
`
`
`
`Yes.
`
`
`
`
`
`
`And it is overall,
`
`
`
`
`
`in my opinion,
`
`
`
`that
`
`
`
`
`
`
`
`
`three—times—a—day Brimonidine is more effective than
`
`
`
`
`
`twice—a—day Brimonidine. And,
`
`
`
`
`in fact,
`
`
`
`that
`
`
`
`
`
`is in my
`
`
`
`
`
`
`
`
`
`
`
`
`expert opinion, and I used a different reference as the
`
`
`
`
`
`
`
`
`main reference for that, specifically Konstas.
`
`
`
`
`
`THE COURT: Doctor,
`
`
`
`
`
`
`she hadn't asked you
`
`
`
`
`
`any of that.
`
`
`
`
`THE WITNESS:
`
`
`
`
`
`
`I'm sorry, Your Honor.
`
`
`
`
`THE COURT:
`
`
`
`
`
`
`
`
`If they want you to repeat
`
`
`
`
`
`
`
`
`
`
`that testimony or what's in your expert report,
`
`
`
`they'll
`
`
`
`
`
`
`
`
`
`
`
`ask you. But unless everybody's not listening to me,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 5 of 166
`
`Page 5 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:O9—cv—00097-JRG Document 241 Filed 08l08l11 Page 6 of 165 Page|D #: 6192
`
`
`
`
`
`
`
`
`
`
`
`the Court's going to start tightening up.
`
`
`
`
`
`I'm not here
`
`
`
`
`
`
`to listen to lectures.
`
`
`
`
`
`
`
`
`I'm here for you to answer
`
`
`
`the
`
`
`
`
`
`
`
`questions asked, and stop talking.
`
`
`
`Are we clear?
`
`
`
`
`
`
`
`
`
`THE WITNESS: Yes, Your Honor.
`
`
`
`
`THE COURT:
`
`
`
`
`Thank you.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`
`(By Ms. Brooks) And let's just see if we can
`
`
`
`
`
`
`
`
`
`
`
`
`find the graph that correlates to this data in PTX134,
`
`
`
`
`
`
`
`
`
`
`
`
`which you don't have before you, Dr- Tanna, because it's
`
`
`
`
`
`
`
`
`
`
`too large, but has previously been discussed with
`
`
`
`
`Ms. Batoosingh.
`
`
`
`
`MS. BROOKS:
`
`
`
`
`
`
`
`
`
`If we can go to PTXI34 and
`
`
`
`
`
`
`
`
`
`specifically at Bates No. 6?6465, Mr. Exline.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Tanna?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`
`(By Ms. Brooks) And do you see this graph, Dr.
`
`
`
`Yes,
`
`
`
`
`I do.
`
`
`
`
`
`
`
`
`
`Could you show the Court where that
`
`
`
`
`
`
`
`
`
`3.5—millimeters of mercury difference occurs between the
`
`
`
`
`
`
`
`
`
`twice—a—day dosing of Alphagan and the three—times—a—day
`
`
`
`
`
`dosing of Alphagan?
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`It's not doing ——
`
`
`
`
`
`
`Here, I'll try to help you.
`
`
`
`
`
`
`
`
`
`
`
`
`I have a pointer. May I use a laser pointer?
`
`
`
`Sure.
`
`Well,
`
`
`
`
`
`
`
`
`
`
`
`Or did I get it close right there?
`
`
`
`
`
`that's it, yes.
`
`
`
`Page 6 of 166
`
`Page 6 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00O9?—JRG Document 241 Filed 08108111 Page 7 of 165 Page|D #: 6193
`
`
`
`
`
`Q.
`
`
`
`Okay.
`
`
`
`
`
`
`
`
`
`
`And so, again, you agree that —— one of
`
`
`
`
`
`
`
`
`
`
`
`
`skill in the art would know, based on this data,
`
`
`
`that
`
`
`
`
`
`
`
`
`
`there was an actual statistically significant decrease
`
`
`
`
`
`
`in the reduction of
`
`
`
`
`
`intraocular pressure at
`
`
`
`
`approximately hour
`
`
`
`
`
`
`9 between the three—times—a—day
`
`
`
`
`
`
`
`
`
`dosing of Alphagan and the twiCe—a~day dosing?
`
`
`
`Yes,
`
`
`
`
`
`in this study.
`
`
`
`
`
`
`
`
`
`
`
`Now, let's move to your discussion of how the
`
`
`
`
`
`A.
`
`Q.
`
`amount of BAK that was claimed would have been obvious.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`You said the BAR was the most common preservative;
`
`
`
`is
`
`
`
`that correct?
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`A.
`
`
`
`
`
`
`
`
`Most commonly used in ophthalmic formulations,
`
`
`
`
`
`
`
`And,
`
`
`
`
`
`
`
`in fact, we saw —~
`
`
`
`
`
`
`
`MS. BROOKS: Mr. Exline, could you pull
`
`
`
`
`
`
`
`
`
`
`
`up Defendants’ Slide 10 that they used in opening
`
`
`
`
`
`
`statement? And if not,
`
`
`
`
`
`
`
`
`
`
`I can always put it on the ELMO.
`
`
`
`There we are.
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`(By Ms. Brooks) So this was
`
`
`
`
`
`
`shown to the Court
`
`
`
`
`
`
`
`
`
`
`
`by the Defendants in opening statement showing all the
`
`
`
`
`
`
`
`
`different drug products that contain BAR.
`
`
`
`
`
`
`
`
`
`Do you agree with that, Dr. Tanna?
`
`
`
`I do.
`
`
`
`
`
`
`
`
`
`
`
`
`
`But let's look at the amount of BAK in these
`
`
`
`
`
`A.
`
`Q.
`
`
`various products.
`
`
`
`
`
`
`
`
`
`
`Isn't it true that there are no less
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 7 of 166
`
`Page 7 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed 08f08:'11 Page 8 of 165 Page|D #: 6194
`
`
`
`
`
`than six different amounts of BAK in these various
`
`
`
`
`
`
`
`
`
`
`
`
`ophthalmic products?
`
`
`
`That
`
`
`
`
`looks right.
`
`
`
`
`Thank you.
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`Let's move on now to your discussion of other
`
`
`
`
`combination drugs.
`
`
`
`
`
`
`
`
`
`You told us about a drug called
`
`
`
`Timpilo;
`
`
`
`
`
`is that right?
`
`
`
`
`
`I did, yes.
`
`
`
`
`
`
`
`And you told us about
`
`
`
`
`
`
`a drug called Cosopt.
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`Of course, we know about that, right?
`
`
`
`Yes.
`
`
`
`
`
`
`
`
`And also a drug called Xalacom;
`
`
`
`
`
`is that right?
`
`
`
`That's correct.
`
`
`
`
`
`
`
`
`
`
`
`
`
`In fact, on Slide 36 that you used, you showed
`
`
`
`
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`both the Timpilo,
`
`
`
`
`
`
`
`the Cosopt, and the Xalacom.
`
`
`
`Now,
`
`
`
`
`
`
`
`in looking more closely at
`
`
`
`
`the Timpilo
`
`
`
`
`
`
`picture that you used,
`
`
`
`
`
`
`
`
`that's not actually a picture of
`
`
`
`Timpilo,
`
`
`
`
`is it?
`
`
`
`A.
`
`
`
`I don't know that —— I can't tell from that
`
`
`
`
`
`
`
`
`
`
`
`picture.
`
`
`
`
`
`I don't know.
`
`
`
`'Q.
`
`
`
`
`Isn't it,
`
`
`
`
`in fact,
`
`
`
`
`
`
`
`just a picture of the
`
`
`
`
`
`bottle of Pilocarpine?
`
`
`
`A.
`
`
`
`
`
`
`
`
`
`
`I don't think so, because it typically would
`
`
`
`
`
`
`have a green cap.
`
`
`
`
`
`
`
`
`
`So I can't tell from this picture.
`
`
`
`
`I
`
`
`
`
`
`
`
`
`am not sure what that's a picture of.
`
`
`
`Page 8 of 166
`
`Page 8 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed 08l08!11 Page 9 of 165 Page|D #: 6195
`
`
`
`
`
`Q.
`
`
`
`Okay.
`
`
`
`
`
`
`
`
`Now, Timpilo has never been approved
`
`
`
`
`
`
`
`
`
`for use in the United States, correct?
`
`
`
`A.
`
`
`
`
`
`
`
`
`
`
`I was under the impression that it was
`
`
`
`
`in use
`
`
`
`
`
`
`
`
`
`in the United States. That's my impression.
`
`
`
`
`
`I could be
`
`
`
`
`
`
`
`
`
`
`
`
`mistaken about it, but my understanding is that it was
`
`
`
`in use in the United States.
`
`
`
`
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`Okay. What about Xalacom; has Xalacom ever
`
`
`
`
`
`
`
`
`
`
`been approved for use in the United States?
`
`
`
`
`
`
`No, it has not.
`
`
`
`
`
`
`
`
`
`Now, while we're talking about Xalacom ——
`
`
`
`
`MS. BROOKS: Let's just
`
`
`
`
`
`leave that up
`
`
`
`
`
`A.
`
`Q.
`
`there,
`
`
`
`
`
`
`
`if we could, Mr. Exline.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(By Ms. Brooks) We're going to revisit some
`
`
`organic Chemistry.
`
`
`
`
`
`
`
`Xalacom is the active ingredient
`
`
`
`in
`
`
`
`Latanoprost;
`
`
`
`
`
`is that right?
`
`
`
`That's correct.
`
`
`
`
`
`And Latanoprost
`
`
`
`
`
`
`
`
`is what's known as a
`
`
`
`A.
`
`Q.
`
`
`
`prostaglandin analog;
`
`
`
`is that Correct?
`
`
`
`That
`
`
`
`is correct.
`
`
`
`
`
`
`
`
`
`Are the prostaglandin analogs normally your
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`first Choice of medication for a new glaucoma patient?
`
`
`
`
`
`
`For me today, yes.
`
`
`
`And,
`
`
`
`
`in fact,
`
`
`
`
`
`
`
`
`the Latanoprost is sold here in
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`the United States as Xalatan;
`
`
`
`is that right?
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 9 of 166
`
`Page 9 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed 08!082‘11 Page 10 of 165 PageID #: 6196
`
`
`l0
`
`
`
`That's correct.
`
`
`
`
`But
`
`
`
`
`
`
`
`
`the Combination of Xalatan and Timolol,
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`
`also known as Xalacom, has never been approved for use
`
`
`
`
`
`
`in the United States;
`
`
`
`
`
`is that correct?
`
`
`
`That is correct.
`
`
`
`
`
`
`
`
`
`
`
`
`And you yourself have never prescribed the use
`
`
`
`
`
`A.
`
`Q.
`
`
`
`for Xalaoom, correct?
`
`
`
`A.
`
`
`
`
`
`
`
`
`I have never prescribed Xalaoom. That's
`
`
`
`
`
`Q.
`
`
`
`Now,
`
`
`
`
`in that
`
`
`
`
`
`
`same category of prostaglandin
`
`
`
`
`
`
`
`analogs, would you put Travoprost?
`
`
`
`A.
`
`
`
`
`
`
`
`
`It is in the same category.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`And that's also known as Travatan;
`
`
`is that
`
`
`
`That's correct.
`
`
`
`
`
`
`
`
`
`
`
`There is no combination drug of Travatan and
`
`
`
`correct?
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`Timolol approved for us in the United States;
`
`
`
`
`is that
`
`
`
`That is correct.
`
`
`
`
`
`
`
`
`
`
`
`
`And also within what you would call a
`
`correct?
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`prostaglandin analog, or we would Call a prostamide,
`
`
`
`is
`
`
`
`
`
`
`a compound Called Bimatoprost.
`
`
`
`
`
`
`
`Are you familiar with that?
`
`
`
`Yes,
`
`
`
`
`I am.
`
`
`
`
`And Bimatoprost
`
`
`
`
`
`
`
`
`is sold here in the United
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 10 of 166
`
`Page 10 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09~cv—00097-JRG Document 241 Filed 08208111 Page 11 of 165 Page|D #: 6197
`
`
`11
`
`
`
`
`
`
`
`
`
`States by Allergan under the name Lumigan.
`
`
`
`
`
`
`
`Are you familiar with that?
`
`
`
`
`Yes,
`
`
`I am.
`
`
`
`
`
`
`
`There are no —— I
`
`
`
`
`think you mentioned that
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`Ganfort, which was a combination of Bimatoprost/Timolol
`
`
`
`
`drug;
`
`
`
`is that right?
`
`
`
`Correct.
`
`
`
`
`
`
`
`
`
`
`
`But Ganfort is not approved for use here in
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`the United States;
`
`
`
`is that correct?
`
`
`
`
`
`No, it's not.
`
`
`
`
`
`
`
`
`
`
`
`
`And just to show how subtle differences make a
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`very big difference, Bimatoprost and Latanoprost, would
`
`
`
`
`you put
`
`
`
`
`
`
`
`
`
`
`
`
`them in the same category as far as mechanism of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`action?
`
`
`
`A.
`
`
`
`
`
`
`
`
`
`
`
`There may be small differences in terms of the
`
`
`
`mechanism of action.
`
`
`
`
`
`I
`
`
`think it's a matter of
`
`
`
`
`
`
`
`controversy.
`
`
`
`
`
`Q. Well,
`
`
`
`
`
`
`
`in fact, Latanoprost is what's known as
`
`
`
`
`17—phenyl—PGF2—alpha, correct?
`
`
`
`
`
`
`
`I know there's a PGF2—alpha~agonist.
`
`
`
`Okay.
`
`
`
`
`
`
`
`
`
`
`And at the Cl position on the alpha
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`chain is an ester;
`
`
`
`
`is that right?
`
`That
`
`
`
`I don't know offhand.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`So I may know a little more organic chemistry.
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`
`What about Bimatoprost? Are you aware that if the C1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 11 of 166
`
`Page 11 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-O0097—.JRG Document 241 Filed 08108111 Page 12 of 165 PagelD #: 6198
`
`
`12
`
`
`
`
`
`
`
`
`
`position on the alpha Chain of Bimatoprost
`
`
`
`
`
`is an amide?
`
`
`
`A.
`
`
`
`
`
`
`
`
`
`
`I believe that I can picture that and agree
`
`
`
`
`
`
`
`with you on that, but
`
`
`
`
`
`
`
`
`I would have to look at
`
`
`
`the
`
`
`
`
`
`
`structure to be sure.
`
`
`
`
`
`
`
`It's a complex —— it's a big
`
`
`
`
`
`
`
`
`
`
`molecule, and I don't know offhand for sure.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`Would you agree with me that an ester is
`
`
`
`different than an amide?
`
`
`
`
`
`
`
`
`It certainly is.
`
`
`
`
`And can,
`
`
`
`
`
`
`
`
`in fact, behave differently in situ?
`
`
`
`
`
`Yes, it can.
`
`
`
`Now,
`
`
`
`
`
`
`
`
`let's go to —- back to the Timpilo.
`
`
`
`You
`
`
`
`
`
`
`
`
`
`
`
`should have in your binder, Dr. Tanna,
`
`
`
`
`
`the label for
`
`
`
`Timpilo,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I hope.
`
`
`
`
`
`
`
`
`
`
`And I don't know if we numbered it
`
`
`
`
`
`
`
`
`
`
`
`
`since it wasn't actually previously in use, but if you
`
`
`
`
`
`
`
`
`
`
`
`
`go through your binder, you should see a label for
`
`
`
`Timpilo.
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`
`Can you tell me approximately where?
`
`
`
`
`
`Oh, it's not
`
`
`
`
`
`in your binder.
`
`
`
`Sorry.
`
`
`
`
`
`
`
`
`
`MS. BROOKS: May I approach, Your Honor?
`
`
`
`THE COURT: Yes.
`
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`(By Ms. Brooks) Now, Dr. Tanna, you've
`
`
`
`
`
`
`
`
`
`referred to Timpilo as a combination drug;
`
`
`
`
`is that
`
`
`
`right?
`
`
`
`A.
`
`
`
`
`
`
`
`It is a combination drug, yes.
`
`
`
`
`Q. Well,
`
`
`
`
`
`
`if we actually --
`
`Page 12 of 166
`
`Page 12 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed U8!08i11 Page 13 of 165 PagelD #: 6199
`
`
`
`13
`
`
`
`
`MS. BROOKS:
`
`
`
`
`
`
`
`
`
`
`If we can go to the ELMO,
`
`Mr. Exline.
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`(By Ms. Brooks} And here's the label for
`
`
`
`Timpilo.
`
`
`
`
`
`cam up there?
`
`
`
`
`
`
`
`
`
`
`
`
`
`THE COURT: Not quite. Here we go.
`
`
`
`
`COURTROOM DEPUTY:
`
`
`
`
`
`
`
`Can you push the doc
`
`
`
`MS. BROOKS:
`
`
`
`
`I sure can. Let's see here.
`
`
`
`
`
`
`
`
`COURTROOM DEPUTY:
`
`
`
`
`Uh—huh.
`
`
`
`
`MS. BROOKS:
`
`
`
`
`
`
`Perhaps —— Mr. Exline, do
`
`
`
`
`
`
`
`
`
`
`you know —— do we have the Timpilo label
`
`
`
`
`
`in the system?
`
`
`
`
`
`We don't? Okay.
`
`
`
`
`
`
`
`It would help if I
`
`
`
`turn it on.
`
`
`
`
`I
`
`apologize.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`There we go.
`
`
`
`
`
`It's my fault.
`
`
`
`
`I'm sorry.
`
`didn't even turn it on.
`
`
`
`
`
`
`
`Q.
`
`
`
`
`
`
`
`{By Ms. Brooks) Dr. Tanna,
`
`
`
`
`
`isn't it a fact
`
`
`
`
`
`
`
`
`
`
`
`
`
`that Timpilo is dispensed in what is described as a
`
`unique,
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`two—ohambered vial system?
`
`
`
`Yes.
`
`
`
`
`
`And one of
`
`
`
`
`
`
`
`the chambers contains a
`
`
`
`
`
`
`
`
`
`concentrated solution of Timolol and Pilocarpine at a pH
`
`
`
`
`
`of approximately 3.5;
`
`
`
`
`
`is that right?
`
`
`
`Correct. Correct.
`
`
`
`
`Now,
`
`
`
`
`
`
`
`
`
`
`
`
`in relation to the pH of the eye, 3.5 is
`
`
`
`
`
`A.
`
`Q.
`
`
`extremely acidic,
`
`
`
`
`
`is it not?
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 13 of 166
`
`Page 13 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed 08108111 Page 14 of 165 Page-ID #: 6200
`1 4
`
`
`
`A.
`
`
`
`It is more acidic than the ocular surface and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`the pH of the eye in general, yes.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`
`
`And the need for this low pH is to prevent the
`
`
`
`
`
`
`
`
`
`hydrolysis of Pilocarpine prior to dispensing;
`
`
`is that
`
`
`
`correct?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`Yes.
`
`
`
`
`
`
`
`
`
`
`
`So you would agree with me, Dr. Tanna,
`
`
`
`that a
`
`
`
`
`
`
`
`
`
`pH can have a significant effect on an active
`
`
`
`ingredient?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`Yes, it can.
`
`
`
`
`
`
`
`
`
`
`And it says the other chamber contains —— can
`
`
`
`
`
`
`
`
`
`you pronounce that word for me,
`
`
`
`
`
`
`
`so I make sure I say it
`
`
`
`
`It's diluent.
`
`
`
`
`
`
`
`
`
`
`
`
`Diluent solution with a pH of 7.8 to 8.2 for
`
`
`
`right?
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`Timpilo 2; and 8.5 to 9.5 for Timpilo 4.
`
`
`
`
`
`
`
`Did I read that correctly?
`
`
`
`
`
`Yes, you did.
`
`
`
`
`
`
`
`
`
`
`And the two solutions are separated by an
`
`
`
`
`
`A.
`
`Q.
`
`
`internal plug?
`
`
`
`Yes.
`
`
`
`
`
`
`
`
`
`
`So this isn't the convenience of having two
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`active ingredients in one bottle, correct?
`
`
`
`A.
`
`
`
`
`
`
`
`
`
`It is a little more complicated than that.
`
`
`
`
`
`
`
`
`
`
`
`
`You have to mix them together effectively by using the
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 14 of 166
`
`Page 14 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-0OO97—.]RG Document 241 Filed 0808/11 Page 15 of 165 PageID #: 6201
`
`
`15
`
`
`
`system.
`
`
`
`Q.
`
`
`
`
`
`
`
`And for whatever formulation reason,
`
`
`
`the
`
`
`
`
`
`
`
`
`
`formulators were not able to simply put
`
`
`
`
`
`the Timolol and
`
`
`
`
`
`
`
`
`
`
`the Pilooarpine into one bottle for shelf life?
`
`
`
`Correct.
`
`
`
`
`
`
`
`
`
`
`And had to go to this two—ohambered system
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`with two different pHs and a plug in the middle;
`
`
`is that
`
`
`
`
`That's right.
`
`
`
`
`
`
`
`Now, another —— so that's the
`
`
`
`right?
`
`
`
`
`
`A.
`
`Q.
`
`
`Pilocarpine/Timolol one.
`
`
`
`
`
`
`
`
`You also mentioned a combination product
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`called Probeta, which is Levobunolol and Dipivefrin?
`
`
`
`
`
`It's pronounced Dipivefrin {pronounces}.
`
`
`Dipivefrin (pronounces).
`
`
`
`
`Thank you.
`
`
`
`
`MS. BROOKS:
`
`
`
`
`
`
`
`Should I push something to
`
`
`
`MR. LOVE:
`
`
`
`
`It's there.
`
`
`
`
`
`MS. BROOKS:
`
`
`
`
`
`There we go.
`
`
`
`
`
`
`think we're
`
`
`
`
`
`
`
`
`
`
`(By Ms. Brooks) And that's called Probeta;
`
`is
`
`
`
`
`
`A.
`
`Q.
`
`
`
`Q.
`
`
`
`
`
`
`that right?
`
`
`
`That's correct. That's available in Canada.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`So that's never been approved for use here in
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`the United States, correct?
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 15 of 166
`
`Page 15 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed 08108411 Page 16 of 165 Page|D #: 6202
`
`
`16
`
`
`
`That's correct.
`
`
`
`
`
`
`
`
`
`
`And you yourself have never prescribed it?
`
`
`
`Correct.
`
`
`
`
`
`
`
`
`
`
`Then we have the Xalacom, which we've already
`
`
`
`
`
`
`talked about,
`
`
`
`
`
`
`
`
`the Ganfort which we've already talked
`
`
`
`
`
`
`
`
`
`about, and then something where it's Travoprost/Timolol
`
`
`
`combination;
`
`
`
`
`
`is that right?
`
`
`
`
`DuoTrav, yes.
`
`
`
`DuoTrav.
`
`
`
`
`
`
`
`
`That also has never been approved
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`for use in the United States, correct?
`
`
`
`A.
`
`Q.
`
`A.
`
`Q.
`
`That's correct.
`
`
`
`
`
`
`
`
`
`
`And you yourself have never prescribed it?
`
`
`
`That's correct.
`
`
`
`
`Now,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I
`
`
`
`
`
`
`
`take it you weren't part of —— well,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`have you ever been part of an FDA approval process for a
`
`
`combination drug?
`
`
`
`
`
`
`
`
`
`
`
`A. Well, we were one of the clinical trial
`
`
`
`centers for DuoTrav for one of
`
`
`
`
`
`
`
`
`the Phase 3 studies in
`
`
`
`
`
`
`
`the U.S.
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`So there were Phase 3 clinical trials
`
`
`
`
`
`
`
`
`
`
`
`conducted on DuoTrav here in the United States, correct?
`
`
`
`A.
`
`
`
`Q.
`
`
`
`
`
`That's correct.
`
`
`
`
`
`
`
`
`
`
`And I assume that you, as one of
`
`
`
`
`the centers,
`
`
`
`
`
`
`
`
`
`attempted to perform those studies accurately, correct?
`
`
`
`A.
`
`
`
`
`
`Yes, we did.
`
`
`
`Page 16 of 166
`
`Page 16 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:O9—cv-0O097—JRG Document 241 Filed O8!08l11 Page 17 of 165 PagelD #: 6203
`
`
`1 7*
`
`
`
`
`
`
`
`
`
`
`
`And attempted to gather the best data that you
`
`
`
`Correct.
`
`
`
`
`
`
`
`
`
`
`And despite your efforts and all the other
`
`
`
`
`
`
`
`
`
`A.
`
`Q.
`
`
`centers’ efforts,
`
`
`
`
`
`to this day,
`
`
`
`
`
`
`
`the FDA has refused to
`
`
`
`
`
`
`
`
`
`
`approve DuoTrav for use in the United States?
`
`
`
`A.
`
`
`
`
`
`
`
`
`That's correct. They're stuck in the
`
`
`
`
`
`approvable letter stage.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`And that's been going on for years, has it
`
`
`
`Correct.
`
`
`
`
`
`
`
`
`
`
`
`Just a couple more areas to cover, Dr. Tanna.
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`You showed us DTXl6? on direct examination.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`That was
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`the Larsson reference, and you said that this showed
`
`
`
`
`
`
`
`
`
`
`
`that the patients —— well, actually, why don't you tell
`
`
`
`
`
`
`
`
`
`
`us your recollection of what this study showed.
`
`
`
`
`A. Well,
`
`
`
`
`
`
`
`
`this looked at normal subjects, not
`
`
`
`
`
`
`
`
`
`
`normal volunteers, and they were dosed with Timolol
`
`
`
`
`
`
`
`
`
`
`
`concomitantly with Brimonidine, each on a sort of BID
`
`
`
`
`
`
`
`
`
`
`
`
`schedule, but only a total of three doses were given.
`
`
`
`
`
`
`
`
`
`
`And then the investigators evaluated the rate of
`
`
`
`
`
`
`production of aqueous humor
`
`
`
`
`
`
`
`
`
`in the eyes as well as the
`
`
`
`
`intraocular pressure.
`
`
`
`
`And what
`
`
`
`
`
`they observed was
`
`
`
`that
`
`
`
`
`
`
`
`the intraocular pressure was lowest
`
`
`
`
`
`
`in the group of
`
`
`
`
`
`
`
`
`
`
`people getting both Timolol and Brimonidine, and the
`
`
`
`Page 17 of 166
`
`Page 17 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv—OU097-JRG Document 241 Filed OBIOBI11 Page 18 of 165 Page|D #: 6204
`
`
`18
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`aqueous production flow rate was also lowest in that
`
`
`
`group.
`
`
`
`
`
`
`
`
`
`
`
`And the pressures were higher in the other two
`
`
`
`
`
`
`
`
`
`
`groups, people getting just Timolol or just Brimonidine.
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`So this would lead one to believe that there
`
`
`
`
`
`
`
`be some benefit to concomitant
`
`
`
`
`
`
`therapy with Timolol
`
`
`Brimonidine, correct?
`
`
`
`
`
`
`
`A.
`
`
`
`
`
`
`
`
`
`
`It sort of validates and explains that when
`
`
`
`
`
`
`
`
`
`
`
`
`
`you use the two together, you get a lower pressure and
`
`
`
`
`
`
`
`
`
`
`
`you get an additive reduction in the production of
`
`
`
`
`
`
`aqueous humor.
`
`
`
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`But this doesn't tell anyone of skill in the
`
`
`
`
`
`
`
`
`
`
`
`art whether one would be able to successfully combine
`
`
`
`
`
`
`
`
`
`
`
`
`these two drugs in the same bottle, correct?
`
`
`
`A.
`
`That
`
`
`
`is correct.
`
`
`
`
`
`
`
`
`
`
`
`And the individuals who were tested in this
`
`
`
`
`
`Q.
`
`
`
`
`
`
`
`reference were actually healthy volunteers and not
`
`
`
`
`
`
`
`
`actually individuals suffering from glaucoma;
`
`
`is that
`
`
`
`right?
`
`
`
`A.
`
`
`
`That
`
`
`
`is correct.
`
`
`
`
`
`
`
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`And there were only a total of
`
`
`
`
`three doses
`
`
`
`That is correct.
`
`
`
`
`
`
`
`And Larsson itself,
`
`
`
`
`
`this reference,
`
`is
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`actually disclosed on the face of all of the patents in
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`this case;
`
`
`
`
`
`is that right?
`
`
`
`Page 18 of 166
`
`Page 18 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-0009?-JRG Document 241 Filed 08!08i11 Page 19 of 165 Page|D #: 6205
`
`
`19
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`A.
`
`Q.
`
`
`
`
`
`That is correct.
`
`
`
`
`
`
`
`
`Now, let's move on.
`
`
`
`
`
`
`You showed and discussed
`
`
`
`
`
`with the Court
`
`
`
`
`
`
`
`
`
`
`the l9T study and the 0 —— 507T study.
`
`
`
`
`
`Do you remember
`
`
`
`that?
`
`
`
`I do.
`
`
`
`
`
`
`
`
`
`
`
`
`Now, neither the l9T study nor the 507T study
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`
`
`
`are prior art to the patents—at~issue;
`
`
`
`
`
`is that correct?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`That
`
`
`
`is correct.
`
`
`
`
`
`
`Now, let's go,
`
`
`
`
`
`if we could,
`
`
`
`
`
`to your written
`
`
`
`
`description opinion.
`
`
`
`
`
`
`
`
`
`
`
`You stated in your opinion that Claims 1, 2,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`and 3 of the 'l49 patent were invalid based on lack of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`written description;
`
`
`
`
`
`is that right?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`That's correct.
`
`
`
`
`
`
`
`
`
`
`
`
`You did not render that opinion in relation to
`
`
`
`
`
`Claim 4, correct?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`That is correct.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Now, Claims 1, 2, and 3 deal with a method of
`
`
`
`
`
`
`
`
`
`treating glaucoma or ocular hypertension by topical
`
`
`
`
`
`administration of about
`
`
`
`
`
`
`.2% Brimonidine by weight
`
`
`
`
`
`
`
`
`to an
`
`
`
`
`eye of
`
`
`
`
`
`
`
`
`
`a person in need thereof, said improvement
`
`
`
`
`
`
`
`
`
`
`
`comprising topically administering to said eye in a
`
`
`
`single composition about
`
`
`
`
`
`
`
`.2% Brimonidine by weight and
`
`
`
`about
`
`
`
`
`
`
`.5% Timolol by weight
`
`
`
`
`
`
`
`
`twice a day as the sole
`
`
`
`
`
`
`
`
`
`
`
`active agents, wherein said method is as effective as
`
`
`
`Page 19 of 166
`
`Page 19 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed 08f08:'11 Page 20 of 165 PagelD #: 6206
`20
`
`
`
`
`administration of
`
`
`
`
`.5% Timolol
`
`
`
`
`
`
`
`twice a day and .2%
`
`
`
`
`
`
`
`
`
`
`
`
`Brimonidine three times a day to said eye, wherein the
`
`
`
`
`
`
`
`
`
`two compounds are administered in separate compositions.
`
`
`
`
`
`Did I get
`
`
`
`
`
`the claim correct,
`
`
`
`
`I hope?
`
`
`
`Yes.
`
`
`
`
`All right.
`
`
`
`Now,
`
`
`
`
`
`
`
`let's look at where the
`
`
`
`
`
`A.
`
`Q.
`
`effectiveness of administration is discussed in the
`
`
`
`
`
`
`
`
`
`
`patent itself.
`
`
`
`
`
`
`
`
`If you would go, please, sir,
`
`
`
`
`
`
`to Column 4 and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`begin with Example 2.
`
`
`
`
`
`
`Do you see that?
`
`
`
`A.
`
`
`I do.
`
`
`
`
`
`
`
`
`
`
`
`
`
`I can go to it in my own exhibit,
`
`
`
`
`
`
`
`because I can't see —— okay.
`
`
`
`
`
`There we go.
`
`
`
`Q.
`
`
`
`
`
`There we go.
`
`
`
`
`
`
`
`So this is saying here,
`
`
`
`
`
`
`this is a study that
`
`
`
`
`
`it's describing, correct?
`
`
`
`
`
`
`In Example 2, yes.
`
`
`
`Yes.
`
`
`
`Uh—huh.
`
`
`
`
`
`
`
`
`
`
`
`And did you have an opportunity, Dr. Tanna,
`
`
`to
`
`
`
`
`
`
`
`
`
`
`
`
`compare the description of this study to the 13T study
`
`
`
`
`
`
`
`
`
`
`that was submitted by Allergan to the FDA?
`
`
`
`I did.
`
`
`
`
`
`
`
`
`
`
`
`Now, were you here when Dr. Whitcup testified?
`
`
`
`I was.
`
`
`
`
`
`
`
`
`
`
`
`Did you hear Dr. Whitcup say that what
`
`
`
`
`the FDA
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 20 of 166
`
`Page 20 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09—cv-00097-JRG Document 241 Filed OBIOSI11 Page 21 of 165 PagelD #: 6207
`
`
`21
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`requires for initial clinical trials of a combination
`
`
`
`
`
`
`
`
`
`
`
`product is that the combination product be compared to
`
`
`
`
`
`
`each of the monotherapies?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`Yes,
`
`
`
`
`
`I heard him say that.
`
`
`
`
`
`
`
`
`
`
`
`
`And you have no reason to disagree with that;
`
`
`
`is that right?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`
`
`I don't disagree.
`
`
`
`
`So what
`
`
`
`
`
`
`
`
`
`
`the FDA wanted to see was the efficacy
`
`
`
`
`
`
`
`
`
`of Combigan as compared to Brimonidine three—times—a—day
`
`
`
`
`monotherapy, correct?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`Yes.
`
`
`
`
`
`
`
`
`
`
`
`And the FDA wanted to see the efficacy of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Combigan as compared to twice—a—day Timolol monotherapy,
`
`correct?
`
`
`
`A.
`
`
`
`
`
`
`
`That was part of what
`
`
`
`
`
`
`
`the FDA wanted to see,
`
`
`
`
`
`Q.
`
`
`
`
`
`
`
`
`
`
`
`
`And if we go on Example 2, which begins at
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Column 4, Line 49, it goes all the way through to the
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`bottom of Column 4, all the way through to the Column 5,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`and all the through to Column 6, 7, 8, and essentially
`
`
`
`
`
`
`
`
`
`
`
`ends at Column 9 where it ends with Example 2;
`
`
`is that
`
`
`
`
`
`right, Dr. Tanna?
`
`
`
`A.
`
`Q.
`
`
`
`
`
`That's correct.
`
`
`
`
`
`And what
`
`
`
`
`
`
`
`
`
`the conclusion as reported of the l3T
`
`
`
`
`
`
`
`
`
`
`study in the patent says: Conclusions —— and I'll stick
`
`
`
`Page 21 of 166
`
`Page 21 of 166
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 2:09-cv-00097-JRG Document 241 Filed 08!08!11 Page 22 of 165 PagelD #: 6208
`
`
`22
`
`
`
`
`
`
`
`
`
`
`
`with the right spe

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket